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Abstract
Objective—To examine the association between baseline bone mineral density (BMD) and
radiographic damage at 3-year disease duration in a longitudinal cohort of African Americans
(AAs) with recent-onset RA.
Methods—Participants (n=141) included AAs with < 2 years of disease duration. All patients
underwent baseline BMD measurement (femoral neck and/or lumbar spine) using DXA. T-scores
were calculated using AAs normative data. Patients were categorized as having osteopenia/
osteoporosis (T score ≤ −1) or healthy. Hand/wrist radiographs, obtained at baseline and at 3-year
disease duration, were scored using modified Sharp/van der Heijde method. The association
between baseline BMD and total radiographic score at 3-year disease duration was examined
using multivariable negative binomial regression.
Results—At baseline, the mean age and disease duration were 52.4 years and 14.8 months
respectively (85.1% women). Average total radiographic scores at baseline and 3-year disease
duration were 2.4 and 5.7. In the final reduced multivariable model adjusting for age, gender, anti-
cyclic citrullinated peptide antibody positivity, and the presence of radiographic damage at
baseline, the total radiographic score at 3-years of disease duration in patients with osteopenia/
osteoporosis at the femoral neck was twice that in patients with healthy bone density and the
difference was statistically significant (p=0.0084). No association between lumbar spine
osteopenia/osteoporosis and radiographic score was found.
Conclusion—These findings suggest that reduced generalized BMD may be a predictor of future
radiographic damage and support the hypothesis that radiographic damage and reduced
generalized BMD in RA patients may share a common pathogenic mechanism.
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The progression of radiographic damage in rheumatoid arthritis (RA) is not uniform (1) and
despite the advent of biologic agents, RA continues to cause joint destruction in a significant
proportion of patients (2–6). Initial radiographic damage, antibodies to cyclic citrullinated
peptide (anti-CCP), C-reactive protein (CRP) levels, and other inflammatory markers are
currently used to identify patients at greatest risk for developing progressive joint damage in
an effort to selectively implement early, aggressive treatment strategies (7–11).
Recent findings among RA patients of European ancestry have suggested that lower bone
mineral density (BMD) at various anatomic sites can be used as a predictor of progressive
radiographic damage. Significant associations between hand BMD and subsequent
radiographic damage in patients with early RA have been reported independently in three
longitudinal studies (12–14). Forslind et al showed that generalized bone loss was a
significant predictor of radiographic progression at 2-year follow-up (15). In addition to
these longitudinal studies, generalized BMD has been shown to be significantly associated
with radiographic damage or joint erosions in a number of cross-sectional studies (16–19).
However, it is unknown whether these results can be extrapolated to African American RA
patients. Healthy African Americans have higher BMD (20–22) and a significantly lower
risk of osteoporosis-related fractures than Caucasians, Asians, and Hispanics (23). African
Americans not only achieve a higher peak bone mass but differ from European Americans
with respect to skeletal resistance to parathyroid hormone, estradiol and testosterone levels,
calcium metabolism, and the rate of bone turnover (24–29).
The objective of this study is to examine whether baseline generalized BMD at the femoral
neck and lumbar spine correlates with radiographic joint damage accrued over time in a
longitudinal cohort of African American patients with recent-onset RA.
Materials and Methods
The analyses were performed in participants enrolled in the Consortium for the Longitudinal
Evaluation of African Americans with Early RA (CLEAR) Registry from 2001 to 2005. The
CLEAR Registry has four sites participating in this longitudinal study, including the
University of Alabama at Birmingham (Coordinating Site), Emory University, the
University of North Carolina, and the Medical University of South Carolina(30). The study
was approved by the Institutional Review Board (IRB) at each participating site and all
participants provided informed written consent.
Briefly, subjects were eligible if their self-reported race was black or African American, if
they had a diagnosis of RA as defined by the American College of Rheumatology (ACR)
1987 classification criteria (31), and if the disease duration was less than 2 years from
symptom onset. At the baseline visit, questionnaires were administered to collect
information on medical history (ACR criteria, extra-articular manifestations, disease
duration, current and past use of RA and non-RA medications, co-morbidities) and
demographics. All patients underwent a physical examination during which information on
height and weight was obtained. The number of tender and/or swollen joints was assessed by
trained evaluators; the Joint Alignment and Motion scale was used to assess joint deformity
(32); and the Health Assessment Questionnaire (HAQ) Disability Index was used to evaluate
functional ability (33). Serum rheumatoid factor (RF-IgM, IU/ml, INOVA Diagnostics,
USA) and anti-CCP antibodies (U/ml, Diastat, Axis-Shield Diagnostics Ltd., UK) were
measured, as previously reported (34). Plasma high-sensitivity C-reactive protein (hs-CRP,
mg/L) concentrations were determined using an immunoturbidimetric assay on the Hitachi
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917 analyzer (Roche Diagnostics - Indianapolis, IN), using reagents and calibrators from
DiaSorin (Stillwater, MN).
Participants were re-evaluated at 3-years disease duration (time elapsed since symptom
onset). Because the CLEAR participants were enrolled at any point less than 2 years after
disease onset, the disease duration at baseline visit varied from 0–2 years. As a result, the
amount of follow-up time also varied among study subjects. Between the baseline and 3-
year visits, patients were surveyed via telephone at 6-month intervals to obtain information
about medication use since the last study encounter.
The outcome variable of our study was radiographic damage at the 3-year follow-up visit.
Radiographs of the hands and wrists were obtained at baseline and at the 3-year visits and
radiographic damage was evaluated using the van der Heijde modified Sharp (SvdH)
method (35). Baseline BMD at the femoral neck and lumbar spine were measured at each
participating center using dual energy x-ray absorptiometry (DXA). BMD measures were
standardized to Hologic BMD using published conversion equation (36) and T-scores were
calculated using referent data from the general African American population:
manufacturer’s reference database (lumbar spine) and National Health and Nutrition
Examination survey-III data (femoral neck). Details with regard to the collection,
standardization, and calculation of T-scores have been previously published (37). Based on
baseline T scores, patients were categorized into two groups for each anatomical site:
“Osteopenia/Osteoporosis” (T-score less than or equal to −1) or “Healthy” (T-score greater
than −1).
Statistical Analyses
Patients in the CLEAR Registry with SvdH score at the 3-year visit and baseline BMD at
either femoral neck or lumbar spine were included in the analysis (n=141). The dependent
variable was the total SvdH score at the 3-year visit, which was a non-negative integer
assuming an over-dispersed Poisson distribution (variance greater than mean). Hence, linear
models were not appropriate and negative binomial regressions were used in both univariate
and multivariable analyses. The exponentiation of parameter estimate (EPE) of the negative
binomial regression model can be interpreted in a multiplicative manner such as in the
following example, e.g., an EPE of 3 for female gender indicates that the total SvdH score
for a female is 3 times that for a male if the two subjects were the same with regard to all
other covariates. An EPE greater than 1 indicates that the presence of the characteristic (or a
higher value in the case of a continuous variable, e.g., older age) is associated with greater
total 3-year SvdH score and an EPE less than 1 indicate the opposite.
A wide range of baseline characteristics were examined in univariate analyses, including
age, gender, body mass index (BMI), disease duration at baseline, baseline plasma hs-CRP
level (mg/L), anti-CCP antibody positivity, RF-IgM positivity, presence of radiographic
damage (SvdH score > 0), HLA-DRB1 shared epitope (SE) positivity (the HLA-DRB1 alleles
encoding the SE were: HLA-DRB1*0101, *0102, *0401, *0404, *0405, *0408, *0413,
*1001, and *1402), cumulative oral glucocorticoid use (a composite of dose, frequency, and
duration) prior to the 3-year visit was categorized approximately into 3 tertiles: never
(n=47), low (n=43), and high (n=44), HAQ score, tender and swollen joint counts, number
of ACR criteria, number of extra-articular manifestations, and smoking status (never, past,
or current smoker).
Age, gender, BMI, cumulative glucocorticoid use, smoking status, and variables that had p-
values less than 0.10 in univariate analyses were included in an initial multivariable model.
To produce a final parsimonious model, the initial model was then manually reduced by
removing variables that had the greatest p-value at each step if they were not statistically
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significant at 0.05 significance level and if the removal of the variables did not produce a
10% or greater change in the parameter estimate for femoral neck or lumbar spine
osteopenia/osteoporosis (38). Because BMD at femoral neck and lumbar spine were highly
correlated, two separate multivariable models were examined for BMD at the two
anatomical sites.
All statistical analyses were performed using SAS statistical package (version 9.1, SAS
Institute Inc., Cary, North Carolina).
Results
Baseline patient characteristics are shown in Table 1. At the baseline visit, the mean (SD)
age and disease duration were 52.4 (13.0) years and 14.8 (7.3) months, respectively. Women
accounted for 85.1% of the total study population. Mean (SD) SvdH scores at baseline and
3-year visits were 2.4 (5.4) and 5.7 (11.3), respectively, with an average annual progression
rate of 1.5 units.
At baseline, the average BMD (g/cm2) at lumbar spine and femoral neck were 1.08 and 0.85.
At lumbar spine 38.6% of the subjects had either osteopenia or osteoporosis and at femoral
neck 44.9% (T-score ≤ −1). Patients with osteopenia/osteoporosis at either anatomical site
had higher mean total SvdH scores at baseline and more progression during the follow-up
period. At femoral neck, the mean total SvdH scores at baseline and 3-year visits in patients
with osteopenia/osteoporosis were 3.31 and 8.16 respectively and in patients who had
healthy bone density the means were 1.76 and 3.91. At lumbar spine, the mean total SvdH
scores at baseline and 3-year visits were 3.10 and 7.63 in patients with osteopenia/
osteoporosis and were 2.00 and 4.58 in patients who had healthy bone density.
Table 2 presents the results of the univariate analyses and the final reduced multivariable
model. Femoral neck osteopenia/osteoporosis at baseline was associated with higher total
SvdH score at the 3-year visit (EPE=2.2; p=0.0249). After controlling for other baseline
characteristics, femoral neck osteopenia/osteoporosis remained significantly associated with
higher total SvdH score in the multivariable analyses (EPE=2.1; p=0.0084). The removal of
age and glucocorticoid use from the multivariable model resulted in a 17% increase and a
21% reduction respectively in the parameter estimate for femoral neck osteopenia/
osteoporosis, which exceeded the 10% cut-off point used in the “change in estimate”
strategy to evaluate confounding (38). While they were not statistically significant at 0.05
alpha level, they were kept in the final multivariable model (Table 2). To test the robustness
of our final model, we built an alternate reduced model retaining only those variables that
are significant at 0.05 alpha level and the results were similar. The 3-year total SvdH scores
in subjects with reduced bone density at the femoral neck were twice those of subjects with
healthy bone density (EPE=2.1; p=0.0035).
Baseline osteopenia/osteoporosis at the lumbar spine was marginally associated with the
SvdH score (EPE=1.8; p=0.0897) in the univariate analysis. There was no final reduced
multivariable model for lumbar spine BMD. Lumbar spine osteopenia/osteoporosis was not
significantly associated with 3-year total SvdH in the full model and was eliminated during
variable elimination.
We excluded two subjects whose 3-year SvdH scores were five standard deviations (SDs)
above the mean and were osteoporotic at baseline in order to evaluate the sensitivity of the
final multivariable model. Reduced bone density at femoral neck remained a significant
predictor of total SvdH score (EPE=2.1; p-value = 0.0093).
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Given that generalized BMD may be more strongly related to bony erosions than to joint
space narrowing or total SvdH scores, we performed additional analyses examining the
relationship between femoral neck and hip osteopenia/osteoporosis with erosion scores at 3-
years disease duration, using the same method described above. Femoral neck osteopenia/
osteoporosis was significantly associated with the 3-year disease duration erosion score in
univariate (EPE=2.2; p=0.0279) and multivariable analyses (full model EPE=2.7;
p=0.0061). A marginally significant association was observed for lumbar spine osteopenia/
osteoporosis in univariate (EPE=2.0; p=0.0535) and multivariable analyses (full model
EPE=1.8; p=0.0594). These results are summarized in table 3.
Discussion
RA patients are at increased risk of developing osteoporosis compared with those without
RA (39). Increasing evidence suggests a common mechanism for generalized bone loss and
localized radiographic joint damage. A number of cross sectional studies have reported a
significant correlation between the two types of bone manifestations(16–19) and agents
targeting tumor necrosis factor (anti-TNF treatment) has been found to halt generalized bone
loss in RA patients in addition to its effect on localized joint damage (40). The mechanism
has been postulated to involve inflammatory cytokines in the regulation of osteoclast
differentiation and activation. Research interest has focused on the RANK/RANKL
(receptor activator of NF-κβ/RANK ligand) pathway and TNF-α (41,42). Our findings of
significant associations between reduced BMD (osteopenia/osteoporosis) at femoral neck
with 3-year total SvdH score and the erosion score in African American patients with recent-
onset RA lends further support to this hypothesis.
Our results raises the question of whether bone density is already reduced in early RA
patients compared with general population. We had obtained bone mineral density data on
approximately frequency age- and gender-matched African American controls (n=161).
Using multivariable linear regression to further control for age and gender, there was a
marginally significant difference for femoral neck BMD (p=0.0767). Given the same age
and gender, the bone density in RA patient was 0.03 point higher than that in a control. This
further suggests that the balance in bone remodeling is already tilted by the disease.
Our findings also have potentially important clinical implications in the treatment of patients
with recent-onset RA by suggesting that generalized BMD may be used as a predictor of
subsequent radiographic damage. The identification of early RA patients with more a
aggressive disease course is of great importance, particularly since prompt initiation of
disease modifying treatments have been shown to protect against joint damage and RA-
related functional and work disability (43,44). Denosumab, an investigational human
monoclonal antibody against RANKL, has been shown to reduce localized joint erosions in
RA patients and to increase bone density in postmenopausal women (45,46). Perhaps, given
the ability of the new agent to treat both types of bone manifestations, reduced BMD can be
used as more than a biomarker to predict future joint damage, but also as a biomarker to
identify patients who are likely to benefit most from such new therapy and as an indication
to initiate the treatment.
We did not find a significant association between baseline lumbar spine osteopenia/
osteoporosis with 3-year SvdH score. The discrepancy that an association was observed
between radiographic joint damage with BMD at the hip but not at the lumbar spine has
been reported previously in patients of European ancestry (16–18). One likely explanation
for the discrepancy is osteoarthritis and/or other vertebral deformities occurring commonly
in elderly population. Osteophyte formation, bone sclerosis, and disk space narrowing have
been found to correlate positively with lumbar spine BMD whereas such a correlation was
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either not observed or observed to a lesser degree with hip BMD (47). The issue that lumbar
spine BMD is often falsely inflated is reflected in the clinical guidelines of the National
Osteoporosis Foundation (NOF), which recommends hip BMD as the preferred site for the
diagnosis of osteoporosis(48).
In our study, peak referent BMD from African Americans was used to derive the T-scores.
Because the objective of the study was not to assess fracture risk but to evaluate the
association between radiographic damage and reduced bone mass, the use of race-specific
referent data allowed us to determine the severity of bone loss and to measure the amount of
reduction from the expected peak BMD. We replicated the same models using BMD as a
continuous variable. Without adjusting for other variables, femoral neck BMD was
marginally associated with the 3-year total SvdH score (EPE=0.21, p=0.0765) and lumbar
spine BMD was not (EPE=0.45, p=0.3239). Adjusting for the same covariates as in the final
reduced model, femoral neck BMD was again borderline significant at p-value 0.0542
(EPE=0.14). While the association did not reach the 0.05 threshold, the results were
consistent with those when the dichotomized measures were used.
There are a number of limitations in our study. First and foremost, the relatively small
sample size (n=141) is likely to have resulted in the exclusion of a number of baseline
characteristics from entering the multivariable analyses. To address this issue, the change-in-
estimate approach has been used to evaluate possible confounders and to fit the final
multivariable model. Perhaps more importantly, because under-powered early studies tend
to report over-inflated effect size (49), the magnitude of the association found in our study
will need to be evaluated and interpreted with caution.
Another limitation of our study concerns the accuracy of the patients’ self-reported
cumulative oral glucocorticoid use. Patients were asked to provide detailed information on
the dose, duration, and type of glucocorticoid used and were then categorized into tertiles of
cumulative glucocorticoid use. While previous research has shown robust agreement
between quartiles of cumulative glucocorticoid dose from self-report and medical records
review (50), it is possible that the self-reported information was inaccurate and patients were
misclassified into the wrong group regarding this important exposure. Misclassification may
result in uncontrolled confounding and inflation of the magnitude of the association between
generalized BMD and radiographic damage we found in our study.
The association between generalized BMD and radiographic damage may be confounded by
multiple factors. In addition to glucocorticoid use, physical inactivity due to impaired
function, body mass index (BMI), disease activity, and medications may all influence the
relationship. A study by Solomon et al. (16) found that the relationship between focal bone
erosions and generalized BMD was stronger among patients with shorter disease duration
and lower cumulative oral glucocorticoid use, suggesting that in patients with longer disease
duration, the other factors exerted greater influence on the relationship between bony
erosions and generalized BMD.
Despite the limitations discussed above, our study is the first to examine the relationship
between generalized BMD and radiographic damage in African American patients with
recent-onset RA. African Americans are under-represented in RA research and the known
racial/ethnic differences in the skeletal system render it unclear whether the previously
reported results apply in this population.
In summary, the findings from our study suggest that generalized bone density may be a
predictor of radiographic damage and provide further support for the hypothesis that the two
types of bone manifestations share a common mechanism. The elucidation of such
mechanism responsible for the imbalance in bone remodeling in future research will not
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only lead to a better understanding of the pathogenesis of RA but also one more step toward
individualized medicine and development of novel treatment therapies that have the
potential of addressing both types of bone involvement.
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Table 1
Baseline characteristics of African Americans with recent-onset rheumatoid arthritis (n=141)
Baseline Characteristics Mean ± SD or n (%)
Women 120 (85.1)
Age (years) 52.4 ±13.0
Disease duration since symptom onset (months) 14.8 ± 7.3
BMI (kg/m2) 31.2 ± 6.7
Patient assessment of pain (on a visual analog scale) 5.9 ± 3.0
HAQ score 1.4 ± 0.8
Number of Swollen Joints (range; 0–38) 5.7 ± 7.5
Number of Tender Joints (range; 0–42) 10.9 ± 11.3
Rheumatoid nodules 19 (13.7)
Number of ACR criteria (range; 4–7) 5.0 ± 0.8
CRP, mg/L 12.3 ± 30.3
IgM RF positive 104 (77.6)
Anti-CCP positive 89 (66.9)
HLA-DRB1 shared epitope positive 69 (50.0)
Presence of baseline radiographic damage (SvdH score >0) 48 (34.5)
*
BMI, body mass index; HAQ, Health Assessment Questionnaire; CRP, C-reactive protein; RF, rheumatoid factor; CCP, cyclic citrullinated
peptide; HLA-DRB1 shared epitope positivity (0101, 0102, 0401, 0404, 0405, 0408, 0413, 1001, and 1402); SvdH, modified Sharp/van der Heijde
score













Zhang et al. Page 12
Table 2
Univariate and multivariable models between baseline characteristics and 3-year van der Heijde modified
Sharp score among African Americans with recent-onset rheumatoid arthritis (n=141)
Univariate analyses Final Reduced
Multivariable Model
Baseline Characteristics EPE† P-Value EPE† P-Value
Demographics
    Age 1.02 0.1693 1.02 0.1513
    Gender (Female) 0.60 0.2745
    Smoking status#
   Never 1.50 0.3312
   Current 1.11 0.8244
Laboratory measures
    Positive IgM RF 2.88 0.0109
    Positive anti-CCP 2.38 0.0188 2.80 0.0028
    CRP 1.01 0.2230
Other RA-related measures
    Disease duration 1.02 0.3865
    Number of ACR criteria 1.25 0.2552
    Number of extra-articular
   manifestations
1.28 0.2261
    Number of tender joints 1.00 0.9072
    Number of swollen joints 1.03 0.2097
    Pain 1.09 0.1681
    HAQ score 1.30 0.2440
    BMI 0.98 0.4165
    Cumulative oral glucocorticoid use
   Low 1.25 0.5994 1.40 0.3667
   High 0.88 0.7575 0.79 0.4698
    Presence of radiographic damage
      (SvdH score >0)
9.43 <.0001 9.60 <.0001
    HLA DRB 1 1.01 0.9776
Femoral neck osteopenia or
osteoporosis (vs. healthy)
2.15 0.0249 2.10 0.0084
†
EPE, exponentiation of parameter estimate
*
BMI, body mass index; HAQ, Health Assessment Questionnaire; CRP, C-reactive protein; RF, rheumatoid factor; CCP, cyclic citrullinated
peptide; HLA-DRB1 shared epitope positivity (0101, 0102, 0401, 0404, 0405, 0408, 0413, 1001, and 1402); SvdH, modified Sharp/van der Heijde
score
**
Baseline variables included in the initial multivariable model included: age, gender, body mass index, smoking status, IgM-rheumatoid factor
positivity, anti-CCP positivity, cumulative glucocorticoid use, presence of radiographic damage, and presence of femoral neck osteopenia/
osteoporosis.
#
Reference group was past smokers
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